Figure 6.

Nivolumab and atezolizumab treatment decrease the percentage of ALDH⁺ stem-like OAC cells in vitro. OE33 cells and SK-GT-4 cells were treated with nivolumab (10 μg/ml), atezolizumab (10 μg/ml) or A2aR antagonist (3 μM) in the absence or presence of the FLOT regimen for 48 h. ALDH activity was determined using an aldefluor assay by flow cytometry. Representative dot plots shown for each treatment and for the DEAB negative control which was used to assess baseline fluorescence to allow accurate gating for ALDH activity. (A) depicts the frequency of ALDH + OAC cells and (B) depicts the median fluorescence intensity of ALDH as a percentage of the vehicle control. Experiments repeated for an n = 4 independent experimental repeats using singlet technical replicates. *p < 0.05 and **p < 0.01, Kruskal–Wallis statistical test.